Gilead plans to submit New Drug Application for Filgotinib to USFDA
Category: #health  By Nikita Chaurasia  Date: 2019-07-03
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Gilead plans to submit New Drug Application for Filgotinib to USFDA

Gilead Sciences, Inc., a biotechnology company recently provided an update about the investigational- filgotinib, selective JAK1 inhibitor, at a pre-NDA (New Drug Application) meeting with the USFDA, cite sources.

For the record, Gilead Sciences, Inc. is a US-based biotechnology firm that focuses on discovering, developing & commercializing innovative medicines in areas of medical needs that have been unmet. The company transforms & simplifies medical care for people with life-threatening illnesses across the world. The company is operational in more than 35 countries across the world and is headquartered in California.

Reportedly, the Phase 3 FINCH studies along with the ongoing Phase 2 MANTA safety study evaluating semen parameters with treatment of filgotinib in men with moderately to severely active ulcerative colitis or Crohn’s disease, were discussed by Gilead with the USFDA. As a result of the discussion, the company intends to submit the New Drug Application for filgotinib as a treatment for rheumatoid arthritis by this year.

The announcement came on the heels of announcement made earlier by Gilead Sciences to collaborate with Carna Biosciences to develop & commercialize small molecule compounds in immune oncology. The biotechnology companies have also entered into a research & development partnership to examine Carna Biosciences’ proprietary lipid kinase drug discovery platform.

As per the conditions pertaining to the license agreement, Gilead Biosciences will retrieve license from Carna Biosciences for rights to create & commercialize inhibitors against target of immuno-oncology target. In relation with this agreement, Carna Biosciences is expected to receive a payment of $20 million & is entitled to receive an additional payment of $450 million upon achievement of certain development & commercial milestones. Carna Biosciences is also expected to receive royalties on future net sales, report sources close to the matter.

Source credits: https://www.gilead.com/news-and-press/press-room/press-releases/2019/7/gilead-announces-intent-to-submit-new-drug-application-for-filgotinib-to-us-food-and-drug-administration-this-year

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

By Nikita Chaurasia

The McPlant patty is developed in collaboration with Beyond Meat Inc. It will be prepared using vegetarian ingredients like peas, potatoes, and rice. McDonald’s will reportedly start offering its first vegetarian option in the U.S., the ne...